SciSparc (NASDAQ:SPRC) Upgraded at Wall Street Zen

Posted by on Jul 21st, 2026

Wall Street Zen upgraded shares of SciSparc (NASDAQ:SPRC – Free Report) to a hold rating in a report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a research report on Tuesday, May 26th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Check Out Our Latest Stock Report on SPRC

SciSparc Stock Down 6.0%

Shares of NASDAQ SPRC opened at $4.70 on Friday. SciSparc has a 1-year low of $2.98 and a 1-year high of $80.10. The business has a 50-day moving average of $6.48 and a 200-day moving average of $6.46.

SciSparc (NASDAQ:SPRC – Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported ($31.60) EPS for the quarter. The company had revenue of $0.20 million during the quarter.

About SciSparc

(Get Free Report)

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.

Featured Articles

Receive News & Ratings for SciSparc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciSparc and related companies with MarketBeat.com's FREE daily email newsletter.